Sign in

CIK 0001785279

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Metagenomi Therapeutics, Inc.

Sign in to watch
Ticker
MGX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
813909017
Phone
+1 510-871-4880
Business address
5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, CA, 94608
Former names
Metagenomi, Inc., Metagenomi Technologies, LLC
Open-market buys, last 90 days
$23,401
in 1 filing
Open-market sales, last 90 days
$5,107
in 3 filings

Net +$18,294. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-09-09 Reid Laurence Director Purchase +19,883 $1.17 $23K 19,883
2026-09-09 Reid Laurence Director Purchase +117 $1.18 $138 20,000
2026-09-08 Wein Matthew See Remarks Sale −358 $1.16 $415 126,133
2026-09-08 Irish Jian See Remarks Sale −2,140 $1.16 $2K 375,393
2026-09-08 Wapnick Pamela Chief Financial Officer Sale −1,911 $1.16 $2K 206,580
2026-06-09 Reid Laurence Director Grant or award · Stock Option (Right to Buy) +17,400 17,400
2026-06-09 Dere Willard H Director Grant or award · Stock Option (Right to Buy) +21,000 21,000
2026-06-09 BJERKHOLT ERIC Director Grant or award · Stock Option (Right to Buy) +21,000 21,000
2026-06-09 Eckhardt Juergen Director Grant or award · Stock Option (Right to Buy) +21,000 21,000
2026-06-05 Wapnick Pamela Chief Financial Officer Sale −2,884 $1.30 $4K 208,491
2026-06-05 Irish Jian See Remarks Sale −3,737 $1.30 $5K 377,533
2026-06-05 Wein Matthew See Remarks Sale −558 $1.30 $725 126,491
2026-04-01 Irish Jian See Remarks Grant or award +46,000 379,770
2026-04-01 Irish Jian See Remarks Grant or award · Stock Option (Right to Buy) +276,000 276,000
2026-04-01 Wein Matthew See Remarks Grant or award +11,000 125,549
2026-04-01 Wein Matthew See Remarks Grant or award · Stock Option (Right to Buy) +68,000 68,000
2026-04-01 Wapnick Pamela Chief Financial Officer Grant or award +24,000 211,375
2026-04-01 Wapnick Pamela Chief Financial Officer Grant or award · Stock Option (Right to Buy) +144,000 144,000
2026-03-05 Wapnick Pamela Chief Financial Officer Sale −1,581 $1.60 $3K 187,375
2026-03-05 Wein Matthew See Remarks Sale −482 $1.60 $771 114,549

Page 1 of 6 · 101 trades